We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Kidney dosimetry during <sup>177</sup>Lu-DOTATATE therapy in patients with neuroendocrine tumors: aspects on calculation and tolerance.
- Authors
Sandström, Mattias; Garske-Román, Ulrike; Johansson, Silvia; Granberg, Dan; Sundin, Anders; Freedman, Nanette
- Abstract
Background: Fractionated therapy with 177Lu-DOTATATE has been reported to be an effective treatment for patients with metastasized neuroendocrine tumors. To optimize the treatment, absorbed doses to risk organs are calculated for the individual patient. For each organ, absorbed dose due to activity in the organ itself (self-dose) and that originating from other organs (cross-dose) are calculated from serial measurements to obtain the activity distribution following treatment. The main aim of the present work were to calculate the cross-dose contribution to the total absorbed kidney dose. Methods: Five hundred patients with neuroendocrine tumors undergoing therapy with 177Lu- DOTATATE were included. Scintigraphic planar whole body images and single photon emission computed tomography/computed tomography (SPECT/CT) over the abdomen were acquired at 1, 4 and 7 days after treatment. Kidney self-dose was calculated based on radioactivity distribution obtained from SPECT/CT. Cross-dose to kidneys was estimated using organ-based analysis of planar whole body images and cross-fire dose factors from Olinda/EXM 1.1. Results: Cross-dose to kidneys in the majority of patients were less than 2% and almost all cross-doses were less than 10%. Cross-dose exceeded 10% only in rare cases of patients with high tumor burden and low absorbed doses to kidneys. Conclusions: The absorbed dose from 177Lu-octreotate to solid organs due to cross-fire is generally low and can usually be neglected.
- Subjects
KIDNEYS; DOSE-response relationship (Radiation); NEUROENDOCRINE tumors; RADIATION dosimetry; RADIONUCLIDE imaging; RADIOTHERAPY; SINGLE-photon emission computed tomography
- Publication
Acta Oncologica, 2018, Vol 57, Issue 4, p516
- ISSN
0284-186X
- Publication type
Article
- DOI
10.1080/0284186X.2017.1378431